The management of testicular cancer has shown remarkable improvement over the last 50 years, starting from radical and morbid management incorporating extensive surgery and radiotherapy to the current state of sophisticated, risk-adapted multimodal strategies aimed at morbidity reduction and patient cure. Several new and exciting advances are coming up in this field, further aimed at reducing patient morbidity. However, before looking towards the future, it is essential to look into the past to take stock of how far we have come in this field. Here we present a review of management of testicular cancer over the last seventy years. A comprehensive nonsystematic literature search of the National Library of Medicine database (PubMed) was done using combinations for the terms – “testis cancer”, “radiotherapy”, “chemotherapy”, “tumor markers”, “retroperitoneal lymph node dissection” and “orchidectomy”. All relevant published articles from 1960 till current date, with available English-language full text, describing details about management modalities for testicular cancer were included. A narrative data synthesis was done given substantial heterogeneity in publication date and case mix. The management of testicular cancer evolved from radical surgery and radiotherapy (in 1960-70 s) to cisplatin-based chemotherapy in the 1970-80 s. Modifications in retroperitoneal lymph node dissection and evolution of tumor markers further modified the management of testicular cancer towards active surveillance. Current management protocols favor risk-adaptive multimodal protocols. Testicular cancer management is a tale of true triumph in a solid organ malignancy. • Testicular cancer management has evolved from radical and morbid surgery to risk-adaptive multimodal therapies • Testicular cancer is a tale of true triumph in a solid organ malignancy • FDA approval of miRNA 371-3p is the most promising recent development in the field of testicular cancer
Bansal et al. (Fri,) studied this question.